ReviewBrain sciences2022
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.
Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Activity-based anorexia enhances glutamatergic synaptic transmission and neuronal excitability within the nucleus accumbens of female mice.Physiological reports · 2026Article
- Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care.Current psychiatry reports · 2026Review
- Ketamine for treatment resistant depression in individuals with eating disorders: a comparison study.Journal of eating disorders · 2025Article
- Decoding the Spectrum of Anorexia Nervosa: Clinical Impact, Molecular Insights, and Therapeutic Perspectives.Biomolecules · 2025Review
- Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.Journal of eating disorders · 2025Article
- Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.Psychopharmacology bulletin · 2025Article
- Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis.Journal of eating disorders · 2025Article
- Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating.Therapeutic advances in psychopharmacology · 2025Article
- Shared and distinct brain activation patterns of acupoints HT7, ST36, and KI4: a task-based fMRI study.Frontiers in neurology · 2025Article
- Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors.Journal of neurochemistry · 2024Article
- Mapping Treatment Advances in the Neurobiology of Binge Eating Disorder: A Concept Paper.Nutrients · 2024Article
- Ketamine, an Old-New Drug: Uses and Abuses.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Microdosing ketamine inbioRxiv : the preprint server for biology · 2023Article
- Pharmacological strategies for appetite modulation in eating disorders: a narrative review.Consortium psychiatricum · 2023Review
- Current Discoveries and Future Implications of Eating Disorders.International journal of environmental research and public health · 2023Review
- Increased Demand for Ketamine Infusions and Associated Complexities.Journal of pain research · 2023Article
- The integrated treatment of eating disorders, posttraumatic stress disorder, and psychiatric comorbidity: a commentary on the evolution of principles and guidelines.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr) antagonist, ketamine, has recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several new indications, including obsessive-compulsive, post-traumatic, and substance use disorder, and shows transdiagnostic potential for EDs, particularly among clinical nonresponders. Hence, the aim of this review is to examine contemporary findings on the treatment of EDs with ketamine, whether used as a primary, adjunctive, or combination psychopharmacotherapy. Avenues for future research are also discussed. Overall, results are encouraging and point to therapeutic value; however, are limited to case series and reports on anorexia nervosa. Further empirical research is thus needed to explore ketamine efficacy across ED subgroups, establish safety profiles and optimize dosing, and develop theory-driven, targeted treatment strategies at the individual patient level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.